seed
Stage
About
Ordaōs uses a proprietary AI-driven platform to design de novo mini-proteins and single domain antibodies for drug discovery, enabling faster development of novel protein therapeutics with improved manufacturability and targeting.
Explore Ordaōs's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.